Comparative Study on Depigmenting Agents in Skin of Color

Autor(en): Liyanage, A.
Liyanage, G.
Sirimanna, G.
Schürer, N. 
Stichwörter: arbutin, 497-76-7; ascorbyl palmitate, 137-66-6; azelaic acid, 123-99-9; hydroquinone, 123-31-9; resveratrol, 501-36-0; arbutin; Article; ascorbyl palmitate; azelaic acid; aziderm; ban a tan; comparative study; controlled study; cream; dark spot corrector; data analysis software; dispersion; drug efficacy; drug formulation; drug safety; female; Fitzpatrick IV/V skin type; human; hydroquinone; hypopigmentation; lipophilicity; Mexameter®; neostrata pigment lightening gel; normal human; ointment; prospective study; resveratrol, adult; skin color; Skin lightening preparations
Erscheinungsdatum: 2022
Herausgeber: Matrix Medical Communications
Journal: Journal of Clinical and Aesthetic Dermatology
Volumen: 15
Ausgabe: 2
Startseite: 12
Seitenende: 17
OBJECTIVE: Skin lightening agents are popular in southern Asia, but there is dearth of evidence on their effectiveness on Fitzpatrick IV/V skin types. This study was designed to assess the depigmenting efficacy of commercially available and specifically formulated ointments using the Mexameter® (MX 18). METHODS: This single center prospective study was performed to test five commercially available preparations (Eldopaque®, Aziderm®, Garnier Dark Spot Corrector®, Ban a Tan Cream® and Neostrata Pigment Lightening Gel) on 28 healthy female volunteers in Phase 1, while five single active ingredients in lipophilic dispersion (hydroquinone 4%, ascorbyl palmitate 1%, resveratrol 1% arbutin 5% and azelaic acid 20%) were tested on a different group of 26 healthy female volunteers in Phase 2. The test agents were applied twice a day for five days per week and continued for six weeks in both study phases. Weekly Mexameter® measurements were obtained from test sites and negative controls. RESULTS: Significant hypopigmentation when compared to untreated controls was observed with Aziderm cream (p<0.05, MWU) and the Neostrata Pigment Lightening Gel (p<0.05, MWU). All formulated preparations showed significant reduction in pigmentation; however, only the arbutin (5%) containing formulation revealed significant attenuation of pigmentation in comparison to the inactive control (p<0.05, MWU). CONCLUSION: All applications containing active ingredients showed significant skin lightening; however, only arbutin was able to demonstrate significant diminution of pigmentation when compared to the inactive control. © 2022 Matrix Medical Communications. All rights reserved.
ISSN: 1941-2789
Externe URL:

Show full item record

Page view(s)

Last Week
Last month
checked on Apr 19, 2024

Google ScholarTM